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Abstract
Atherosclerosis, or hardening of the arteries, is a condition in which plaque,
made of cholesterol, fatty substances, cellular waste products, calcium, and fi‐
brin, builds up inside the arteries. A metallic stent is a small mesh tube that is
used to treat these narrowed arteries such as coronary artery diseases. The
drug-eluting stent has a metallic stent platform coated with drug-polymer mix
and has been shown to be superior to its metallic stent counterpart in reducing
restenosis. In the past few years, a novel variation of the drug-eluting stent
with micro-sized drug reservoirs (depot stent) has been introduced to the mar‐
ket. It allows smart programmable drug delivery with spatial/temporal control
and has potential advantages over conventional stents. The drug-polymer mix
compound can be altered from one reservoir to the next, allowing a highly-
controlled release of different medications. For example, this depot stent con‐
cept can be applied in the renal indication for potential treatment of both renal
artery stenosis (upstream) and its associated kidney diseases (downstream) si‐
multaneously. However, the creation of such drug reservoirs on the stent
struts inevitably compromises its mechanical integrity. In this study, the effects
of these drug reservoirs on stent key clinical attributes were systematically in‐
vestigated. We developed finite element models to predict the mechanical in‐
tegrity of a balloon-expandable stent at various stages of its function life such
as manufacturing and acute deployment, as well as the stent radial strength
and chronic fatigue life. Simulation results show that (1) creating drug reser‐
voirs on a stent strut could impact the stent fatigue resistance to certain de‐
grees; (2) drug reservoirs on the high stress concentration regions led to much
greater loss in all key clinical attributes than reservoirs on other locations; (3)
reservoir shape change resulted in little differences in all key clinical attributes;
and (4) for the same drug loading capacity, larger and fewer reservoirs yielded
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higher fatigue safety factor. These results can help future stent designers to
achieve the optimal balance of stent mechanical integrity and smart drug de‐
livery, thereby opening up a wide variety of new opportunities for disease
treatments. We also proposed an optimized depot stent with tripled drug ca‐
pacity and acceptable marginal trade-off in key clinical attributes when com‐
pared to the current drug-eluting stents. This depot stent prototype was
manufactured for the demonstration of our design concept.
Keywords: Drug-eluting stent, Drug reservoir, Depot stent, Mechanical integrity, Smart
drug delivery
1. Introduction
Percutaneous coronary intervention (PCI), also known as angioplasty, has been the current
standard for the treatment of coronary artery diseases. A metallic stent is a tiny, coiled wire-
mesh tube that can be deployed into an artery and expanded using a catheter during angio‐
plasty to open a narrowed artery. However, intimal cells can proliferate due to the artery injury
during stenting, often leading to in-stent restenosis of the artery. Restenosis, the re-narrowing
of the artery after the intervention, is the most common occurrence after angioplasty proce‐
dures in early days [1-3].
In the past decade, stent technology has evolved from the metallic stent to the so-called drug-
eluting stent (DES). A drug-eluting stent has a metallic stent platform coated with an anti-
proliferative drug (e.g., Sirolimus or Everolimus) that is known to interfere with the restenosis
process. The drug is typically mixed with a polymer compound (durable or biodegradable) to
precisely control its release rate and timing to the artery wall. The adoption of the drug-eluting
stent has resulted in a dramatic lowering in restenosis rates from 20 to 30% for the metallic
stent to the single digit now [4, 5], leading to a worldwide embrace of this new technology in
healthcare. Since the introduction of the drug-eluting stent, restenosis has become less of an
issue for the treatment of coronary artery diseases. The drug-eluting stent has thus become the
gold standard for PCI procedures since then.
Although the drug-eluting stent has been hugely successful in lowering restenosis, the stenting
technology continues to evolve in a quest for better solutions. The biodegradable vascular
scaffold (BVS) presents the next frontier. Biodegradable stents stay in the blood vessel for a
limited period of time, give mechanical support, and then degrade to non-toxic substances.
Potential advantages of having the stent disappear from the treated site include reduced late
stent thrombosis, facilitation of repeat treatments to the same site, and freedom from fracture-
induced restenosis. The biodegradable stents with poly lactic acid (PLA) have good physical
properties such as high strength and processability; and in a suitable disposal site it will
degrade to natural products [6-8]. BVS has the potential to act as local drug delivery systems.
Therefore, it is possible to design a BVS, not only offering a physical support to the vessel wall,
but also presenting a pharmacological approach in the prevention of thrombus formation and
intimal proliferation [9-11].
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In recent years, another novel concept in smart drug delivery is the emergence of the depot
stent: a metallic stent laser-drilled with micro-sized holes, or called “reservoirs,” that can be
loaded with single or multiple drugs, potentially in various doses or formulations [12, 13]. The
drug-polymer mix can be varied from one reservoir to the next, allowing a high flexibility of
controlled release of different drugs. For example, on the outer side of the reservoirs close to
the artery wall, drugs preventing neointimal proliferation can be filled, while on the inner side
of the reservoirs close to the blood stream, thrombocyte inhibitors can be filled to prevent stent
thrombosis (Figure 1). In addition, it is believed that this stent concept could become even
more powerful in some cases such as the renal indication for potential treatment of both renal
artery stenosis (RAS) and its associated kidney diseases at the same time, as renal artery
stenosis is usually related to progressive hypertension, renal insufficiency, or kidney failure
reciprocally. For example, drugs preventing neointimal proliferation can be applied on the
outside portion of the reservoirs closer to the artery wall, whereas on the inside portion of the
reservoirs, drugs for kidney diseases can be loaded and carried by the blood stream to the
distal kidney organ for direct target therapy. This proposed method could potentially help to
treat two problems in one attempt. Figure 2 shows that different types of drugs can be
administered independently at each stage after intervention.
The depot stent has other advantages. Unlike drug-eluting stents, the depot stent does not
need to be surface-coated. Therefore, it is free of surface coating layers, thereby reducing direct
contact between the artery wall and the polymer compound. Such contact is believed to
increase the potential risk of chronic inflammation or late stent thrombosis. Another advantage
is the decrease of the overall stent profile due to the absence of surface coating layers. Lower
stent profile allows a stent to access narrower lesion sites and offers physicians easier deliv‐
erability. Given these potential advantages, however, creating reservoirs on the stent struts
inevitably weaken the stent structure and compromise its mechanical integrity, namely, its
abilities to sustain various loading conditions including crimping onto a balloon catheter
during manufacturing, stent expansion during deployment, radial resistance to blood vessels
from collapsing inward, and long-term fatigue resistance to systolic/diastolic pressure
loadings. Therefore, the objective of this paper is to investigate the impact of the micro-sized
reservoirs on the overall mechanical integrity of the depot stent.
Computational modeling has emerged as a powerful tool for optimization of stent designs and
can be used along with bench testing to improve stent clinical performance [14-18]. Such
computational tools could provide valuable insights to various aspects of stent design tactics
which may consequently reduce the potential risk of vascular injury and restenosis. It also
gives extensive information under a highly-controlled environment, making it feasible to
screen numerous design iterations prior to costly prototyping. Therefore, in this study,
computational models were developed to assess key clinical attributes of the depot stent using
finite element analysis (FEA). Based on these findings, we propose an optimal depot stent
design in an effort to increase the drug capacity without significantly comprising its mechan‐
ical integrity.
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2. Depot stent configuration
An L-605 cobalt–chromium balloon-expandable stent was used as the “standard” stent for
baseline in this study. Micro-sized drug reservoirs were created on this standard stent struts
in order to investigate their effects on the stent mechanical integrity. The stent was designed
to form a series of nested rings interconnected with bridging connectors (CO). The design
parameters such as crown radius (CR) and strut dimension were tailored to optimize the
overall stent performance.
Figure 1. Depot stent concept with different types of drugs and release rates administered independently of opposite
sides of the stent.
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The standard stent, which has exactly the same geometry as the investigated depot stents but
without drug reservoirs, was first evaluated to establish the baseline information. The FEA
simulation was then conducted to investigate the effects of reservoir location on the mechanical
integrity of the depot stent. Five equally spaced circular (cylindrical if considering depth)
reservoirs were created on three major locations of the depot stent, namely, connectors, bar
arms (BA), and crowns (Figure 3). The diameter of each circular reservoir was 50% of the strut
width, whereas the reservoir depth was varied for evaluation. The spacing between two
adjacent reservoirs was 0.15 mm, as defined by the length between two reservoir centers along
the strut centerline. The choice of the reservoir number and size was based on the condition
that the total reservoir capacity of the drug–polymer mix inside the reservoirs of the depot
stent was able to fully replace the total volume of surface coating layers on a typical drug-
eluting stent with an average coating thickness of 5μm [4].
Since adding more reservoirs increases the total drug capacity, investigation was also carried
out on the depot stent with reservoirs uniformly spread on the entire stent to understand
whether the mechanical integrity of such a depot stent is further compromised or not (Figure
3(d)). In this special case, the entire stent was covered by reservoirs with the same circular
diameter and depth aforementioned. Another method of increasing the total drug capacity is
by drilling through-holes instead of blind-holes into the stent struts. Therefore, FEA simulation
was also conducted to investigate the effects of reservoir depth on the mechanical integrity.
Further studies were conducted on the depot stent to investigate whether the reservoir shape,
size, and number affect the stent mechanical integrity or not.
Figure 2. Schematic of sequential release of multiple drugs for each period after intervention.
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3. Computational model development
3.1. Stent mechanical integrity assessment
On 18 April 2010, the US Food and Drug Administration (FDA) published an official document,
“Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and
Associated Delivery Systems,” to serve as a guide for the medical device industry. In addition
to the routine stent dimensional tests such as dimensional verification, percent surface area,
foreshortening, and recoil, this document lists several key clinical relevant functional attributes
in which the FDA is interested when reviewing future new stent submissions. For the balloon-
expandable stent, these key clinical attributes include radial strength, stresses–strains, and
fatigue resistance. Each of these properties can serve as an indicator with respect to various
aspects of the stent integrity. In this study, three key clinical attributes were used to assess the
mechanical integrity of the depot stent.
3.1.1. Radial Strength (RS)
One of the most important functions of the stent is to create a scaffolding structure in the artery
and exert radial force against the artery wall to prevent its reclosure. Radial strength represents
the ability of a stent to resist radial collapse under external pressure loadings exerted by the
artery wall. It is defined as the maximum pressure at which the stent experiences irreversible
deformation.
Figure 3. Depot stent with reservoirs on (a) connectors, (b) bar arms, (c) crowns, and (d) entire stent surfaces.
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3.1.2. Equivalent plastic strain (PEEQ)
Since the in vivo deployment of a balloon-expandable stent involves large plastic deformation,
the equivalent plastic stresses and strains have to be calculated throughout the stent. This stress
analysis provides a risk assessment of acute device failure. The stress or strain contour plots
provide the overall distribution of plastic stresses or strains and identify the most fracture-
prone locations of a stent. Stent fracture may cause loss of the radial strength or perforation of
the blood vessel by the fractured stent struts.
3.1.3. Fatigue Safety Factor (FSF)
Stent fracture due to long-term pulsatile fatigue loading may result in loss of the radial
strength, thrombus formation, focal restenosis, or perforation of the blood vessel by the
fractured stent struts. FDA recommends using a Goodman life analysis to determine the
fatigue resistance of a stent to clinically relevant pressure loadings up to 4×108 cycles. The
Goodman life analysis, combined with the stress analysis aforementioned and accelerated
fatigue bench testing, provides a comprehensive risk assessment of long-term stent durability.
The resulting fatigue safety factor shows how safe a stent is from fatigue failure based on the
Goodman life analysis.
3.2. Finite element analysis
3.2.1. Finite element model
A stent deployed in the vasculature system is subjected to various loading modes which may
consequently compromise the stent mechanical integrity during its service life. In this study,
finite element models were developed to evaluate the mechanical integrity and fatigue
resistance of a stent to various loading conditions involved in manufacturing and deploying
a stent consistent with the current practice. The entire stress–strain history of the stent in each
loading step was considered to incorporate the effects of accumulated residual stress–strains
throughout the procedures. It includes manufacturing (crimped onto a balloon catheter), in
vivo deployment (expanded into an artery), and their corresponding recoil and pulsatile
loading subjected to systolic/diastolic pressures. The FEA simulation determines the distribu‐
tion of stress and strain, fatigue safety factor, and radial strength imposed by the following
steps:
Step 1. Crimping a stent from 2.54 mm to 2 mm OD (crimp).
Step 2. Removing outer constraint to allow stent recoil after crimping (crimp-recoil).
Step 3. Expanding a stent to 6.0 mm ID (expansion).
Step 4. Removing inner constraint to allow stent recoil after expansion (expansion-recoil).
Step 5. Applying 180/80 mmHg systolic/diastolic pressures for stent fatigue assessment (or
applying external pressure for radial strength assessment).
It should be noted that step 5 can be used to calculate either the fatigue safety factor or radial
strength of a stent.
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3.2.2. Stent geometry and meshing
The ABAQUS/standard finite element solver (Dassault Systemes Simulia Corp., Providence,
RI, USA) was used to perform the stent FEA analysis. Since a stent has repeated patterns in its
axial and circumferential directions, three representative rings instead of the entire stent were
modeled to save computational time (Figure 3). In order to simulate the manufacturing (crimp
onto a balloon catheter) and in-vivo deployment (expansion inside an artery) steps, two rigid
cylinders with diameters of 2.54 and 1.12 mm were incorporated into the stent model with one
cylinder inside the stent and the other one outside the stent. Gervaso et al. and De Beule et al.
demonstrated that using the displacement-control expansion of a rigid cylinder for simulation
of a balloon expansion could provide reliable and accurate information regarding the stent
shape, stress–strain behavior, etc., when reaching the stent nominal diameter [19, 20]. There‐
fore, the displacement-control simplification was used in this study, as it is computationally
less expensive than simulations involving balloon-driven expansion. Our goal is to assess the
impact of drug reservoirs to the “standard” stent on a relative scale, so the displacement-
control expansion serves that purpose well.
The stent model was meshed with the eight-node linear brick element in incompatible mode
(C3D8I) with the element size of one-sixth of the strut width and one-third of strut thickness.
This specific mesh size was chosen after a mesh sensitivity study to ensure that stress–strain
variation on the stent was adequately captured. The inside and outside rigid cylinders were
meshed with the four-node quadrilateral surface element (SFM3D4).
3.2.3. Material properties and boundary conditions
The material properties of L-605 cobalt–chromium alloy along with the ABAQUS von Mises
plasticity model with isotropic hardening for large deformation analysis were used. Its
Young’s modulus, Poisson ratio, yield stress, ultimate stress, ultimate strain, and fatigue
endurance limit are 203 GPa, 0.3, 590 MPa, 1689 MPa, 60%, and 483 MPa, respectively.
A frictionless contact was used to prevent penetration between two surfaces of the model
during crimping and expansion, with the following contact pairs implemented:
1. The first contact pair was defined as the surface contact between the inner surface of the
outer rigid cylinder and the outer surface of the stent.
2. The second contact pair was defined as the surface contact between the outer surface of
the inner rigid cylinder and the inner surface of the stent.
3. The third contact pair was defined as the side contact between any two stent struts during
crimping.
3.2.4. Stent stress–strain analysis
In step 1, stress–strain analysis was conducted to simulate the crimping of a stent onto a balloon
catheter. The outer rigid cylinder was compressed in the radial direction with the displacement
control, forcing the stent to collapse inward. In step 2, stent recoil after crimping due to elastic
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strain energy was modeled by removing the outer rigid cylinder to allow for the stent recovery.
In step 3, to simulate the in-vivo deployment, the inner rigid cylinder was expanded in the
radial direction with the displacement control to simulate the stent deployment to the target
size. In the final step, stent recoil after expansion due to elastic strain energy was modeled by
removing the inner rigid cylinder to allow for the stent recovery. Figure 4 demonstrates the
configuration of the stent and rigid cylinders at each step of the modeling scheme.
Figure 4. Configuration of the stent/cylindrical surfaces at each stage of the loading scheme: (a) crimp, (b) crimp-recoil,
(c) expansion, and (d) expansion-recoil.
3.2.5. Stent Goodman life analysis
Following the previous four steps, systolic/diastolic arterial blood pressures of 180/80 mmHg
were applied to simulate the pulsatile fatigue loading. In order to account for the external
loading exerted by the arterial wall, an arterial pressure loading corresponding to the inter‐
action between the stent and the artery was also imposed on the stent. The Goodman life
analysis was performed using the multi-axial stress state experienced during the pulsatile
fatigue loading to determine the fatigue resistance of a stent after implant [14]. It states that
fatigue failure will occur if the stress state satisfies the following relationship:
1a m
e u
s s
s s
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(1)
where σ a is the stress amplitude applied to the stent, σ e is the modified material endurance
limit for nonzero mean stress, σ m is the mean stress applied to the stent, and σ u is the material
ultimate strength.
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The Goodman diagram is a plot of the normalized stress amplitude σ a/ σ e (on the y-axis) versus
the normalized mean stress σ m/ σ u (on the x-axis). The equation (σ a/ σ e) + (σ m/ σ u) =1 represents
the failure line on the Goodman diagram for nonzero mean stress with the modified endurance
limit defined as:
0 1 me e
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(2)
where σ e0 is the material endurance limit for zero mean stress. The fatigue safety factor (FSF)
is defined as the ratio of the modified endurance limit divided by the stress amplitude. An FSF
smaller than 1.0 indicates the fatigue failure:
e
a
FSF ss= (3)
4. Depot stent manufacturing
4.1. Laser cutting by integrated laser module
When making a stent, a design drawing is first sketched on the 2D plane, wrapped around a
target cylinder, and coded into the 3D cylindrical coordinate using the CAD/CAM software.
The coded stent geometry is then input into the laser cutting machine and the design pattern
is cut onto a seamless hypotube of 1–2 mm. During the laser cutting process, the hypotube was
rotated and translated in the axial direction by the motor stage while the laser source remained
stationary.
In this study, a laser module consisting of a 100W Yb-doped pulsed fiber laser (Rofin-Baasel
Taiwan Ltd.), a linear X-Y motor stage (Aerotech, Inc.), and a Z-direction server motor was
assembled and integrated (Figure 5). The precision motor stage provides linear motion and
rotation of the hypotube, whereas the Z-direction server motor controls the distance between
the laser source and hypotube surface for the optimal focal position (Figure 6). The X-Y motor
stage accuracy is ±2 μm and ±25 arc-second in the axial and circumstantial direction, respec‐
tively; on the other hand, the linear encoder resolution for the Z-direction server motor is up
to 0.5 μm. Position synchronized output (PSO), a control algorithm that greatly enhances the
efficiency and quality of the laser cutting, was used to coordinate the linear X-Y motor stage
with the timing of laser firing. It can minimize the heat-affected zone (HAZ) during the laser
cutting process. A3200 controller (Aerotech, Inc.) allows us to perform up to 32 axes of
synchronized motion control and therefore could accomplish very sophisticated laser cutting
patterns effortlessly.
The principles of laser cutting and drilling are based on fusion cutting, which involves a
melting mechanism where the heated materials transformed into a molten state are expelled
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from the cut kerf by a high pressure assisted gas such as nitrogen or argon. Laser cutting quality
is typically controlled by several input laser parameters such as focal position, average laser
power, pulse repetition rate, assisted gas pressure, etc. An appropriate position of the laser
focal spot significantly improves the cutting outcome. The focal position of our laser module
was assessed by measuring the kerf width on the hypotube while adjusting the distance
between the laser source and hypotube surface. The smallest kerf width can be achieved by
precisely focusing the laser sweet spot on the hypotube surface. A proper selection of laser
power is crucial to the outcome as well, as excessive laser power results in a wider kerf and a
thicker recast layer. On the other hand, insufficient laser power produces dross due to
incomplete melting [21, 22]. Pulse repetition rate is another important laser parameter related
to surface roughness and material removal. A higher pulse repetition rate corresponds to a
better cutting surface and more effective material removal. Inert gas is a favorable assisted gas
since it can avoid oxidation of the materials. High pressure inert gas was used during the
cutting process to enhance drag forces and achieve high cutting quality [23].
Figure 5. Integrated laser module with a magnified view of the linear X-Y motor stage and laser source in the right
window.
Figure 6. Stent design pattern cut onto a seamless hypotube by laser.
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4.2. Surface finishing by electro-polishing
The laser cutting process inevitably generates dross, heat-affected zone, and other defects at
stent surface. To achieve high quality of mirror-like surface, electro-polishing was performed
on laser-cut depot stent prototypes. A 100 ml glass beaker was used as a bath. The experiment
setup used for electro-polishing is illustrated in Figure 7. The stent was used as an anode,
whereas the cathode was made of a thin lead sheet. The electrolyte consisted of 60 wt%
phosphoric acid (H3PO4), 20 wt% sulfuric acid (H2SO4), and 20 wt% distilled water. Electro-
polishing process was performed with continuous stirring of electrolyte to prevent oxygen
bubbles from adhering to stent surface. Furthermore, several important polishing parameters
including bath temperature, current, and time were determined through experiments to find
the optimal conditions for electro-polishing of depot stents. The stents were then cleaned
ultrasonically using distilled water for 5 minutes and were dried by air blowing as the final
step.
Figure 7. Experimental setup for electro-polishing of depot stent prototypes.
5. Results and discussion
5.1. Effects of reservoir location on stent mechanical integrity
The “standard” stent was first evaluated to establish the baseline information for this study.
The FEA simulation was then conducted to investigate the impact of reservoir location on the
mechanical integrity of the depot stent (e.g., equivalent plastic strain, radial strength, and
fatigue safety factor). Five equally spaced circular (cylindrical if considering depth) and blind-
hole reservoirs were cut on three major locations of the depot stent, namely, connectors, bar
arms, and crowns (Figure 3).
From Table 1, it is clear that the creation of blind-hole reservoirs on either bar arms or con‐
nectors resulted in little or no change in equivalent plastic strain and radial strength. However,
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the degradation in the fatigue safety factor was the most significant among major clinical
attributes investigated, with a 16–18% reduction compared to the “standard” stent. This
indicates that the depot stent with reservoirs on the bar arms or connectors is resistant to vessel
collapse or acute stent fracture but susceptible to long-term stent fatigue failure. In other words,
the depot stent is more sensitive to dynamic loading than static loading.
However, the depot stent with blind-hole reservoirs on the crowns led to noticeable changes
in equivalent plastic strain (+12%) and radial strength (–8%). Its fatigue safety factor declined
further from the standard case of 3.05 to 2.33, a significant 24% reduction. By comparing these
three reservoir locations, it is clear that cutting reservoirs on the stent crowns has the most
significant impact among the three major locations investigated. This is not surprising
considering the standard case that the maximum von Mises stress and maximum equivalent
plastic strain always occur on the inner surface of the curved crowns, whereas the connectors
and the bar arms are mostly under elastic deformation.
Model RS(N/mm)
Variation
(%)
PEEQ
(%Strain)
Variation
(%) FSF
Variation
(%)
Standard 3.78 - 40.5 - 3.05 -
Hole- CO 3.77 -0.26 40.2 -0.74 2.56 -16.07
Hole- BA 3.66 -3.17 39.7 -1.98 2.49 -18.36
Hole- CR 3.49 -7.67 45.2 11.6 2.33 -23.61
Hole- All 3.45 -8.73 45.1 11.36 2.17 -28.85
Table 1. Effects of reservoir location on stent mechanical integrity (blind-hole reservoirs).
Adding the number of reservoirs increases the total drug capacity of the depot stent. Therefore,
investigation was also conducted for reservoirs evenly spread on the entire stent to understand
whether the mechanical integrity of such a stent is further compromised or not (Figure 3(d)).
Simulation results show that this specific depot stent followed a similar trend to the previous
case (blind-hole reservoirs on the crowns only). Their equivalent plastic strain and radial
strength were almost identical, whereas the fatigue safety factor continued to decline further,
with a 29% reduction compared to the “standard” stent. This again demonstrates that the
mechanical integrity of the depot stent is mainly dominated by the reservoirs located on the
stent crowns.
5.2. Effects of reservoirs depth on stent mechanical integrity
Another method of increasing the total drug capacity is to cut through-holes instead of blind-
holes into the stent struts. The through-hole reservoir design also allows different types of
drugs with different release rates to be administered independently on opposite sides of the
stent. Since this dual-side drug delivery concept is quite interesting, simulation was then
carried out to investigate the effects of reservoir depth on the mechanical integrity of the depot
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stent. The depth of the reservoirs was increased from 50% to 75% and 100% of the strut
thickness, with the last case equivalent to the through-hole scenario.
Table 2 summarizes the effects of reservoir depth on the key stent attributes for the case of
depot reservoirs evenly spread on the entire stent. Figures 8 and 9 show the contour plot
comparisons of the equivalent plastic strain developed during different stages of the loading
process (crimping and expansion, respectively) between the standard case and the depot stent
with through-hole reservoirs on the entire stent. It shows again that the maximum equivalent
plastic strain occurred on the inner surface of the most critical region of the stent, the curved
crowns. The maximum equivalent plastic strain was increased by 16%, and its strain distribu‐
tion, as indicated by the colors, changed significantly due to the appearance of the through-
hole reservoirs on the stent crowns. It was more evenly spread along the crown arc for the
standard case but became non-uniform when the maximum stress–strain occurred at the 6
o’clock location of each reservoir.
Model RS(N/mm)
Variation
(%)
PEEQ
(%Strain)
Variation
(%) FSF
Variation
(%)
Standard 3.78 - 40.5 - 3.05 -
Hole- All
(50%) 3.45 -8.73 45.1 11.36 2.17 -28.85
Hole- All
(75%) 3.33 -11.9 46.8 15.56 2.06 -32.46
Hole- All
(100%) 3.08 -18.52 46.8 15.56 2.02 -33.77
Table 2. Effects of reservoir location on stent mechanical integrity (blind-hole reservoirs).
Figure 10 shows the radial strength comparison between the “standard” stent and the depot
stent with through-hole reservoirs on the entire stent. The radial strength dropped by 19% in
this case, and its peak value shifted toward the right by 0.1 mm when compared to the
“standard” stent. This suggests that the through-hole depot stent is not as strong as its standard
counterpart and could be collapsed by the arterial pressure at an earlier stage. Figure 11 shows
the Goodman diagram comparison of the pulsatile fatigue loading between the “standard”
stent and the depot stent with through-hole reservoirs on the entire stent. Simulation data of
the “standard” stent were far below the Goodman diagram failure line, indicating that the
“standard” stent is able to pass the fatigue life of 4 x 108 cycles with ease under pulsatile fatigue
loading. Comparing Figure 11 (top) with Figure 11 (bottom), wherein the same stent but with
through-hole reservoirs was evaluated for pulsatile fatigue loading, shows that the simulation
data of the depot stent migrated toward the Goodman diagram failure line, indicating a
significant drop of 34% in FSF and thus much lower fatigue resistance to systolic/diastolic
blood pressures in this specific case.
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Figure 8. Contour plot of the PEEQ of the standard stent (top) and the depot stent with through-hole reservoirs (bot‐
tom) at crimping with a magnified view of the stent crown in the right window.
Figure 12 shows the effects of reservoir depth on the key stent attributes of the depot stent
with the reservoir depth ranging from 50%, 75% to 100% of the strut thickness on the entire
stent. It is shown that the radial strength decayed almost linearly with the reservoir depth.
The loss in radial strength reached the maximum, a 19% reduction compared to the standard
case, when the reservoirs were completely cut through. The equivalent plastic strain rose
moderately with the reservoir depth but eventually reached a plateau for an approximate‐
ly 15–20% gain. The fatigue safety factor remained the most critical factor among these key
stent attributes. According to the chart, it fell significantly right from the beginning, even
with shallow blind holes, but eventually reached a plateau and settled with an approximate‐
ly 30–35% loss when compared to the standard case. Since the major stent clinical attrib‐
utes suffered significant losses,  it  is  not a good idea to pursue this  specific  design with
through-hole reservoirs spread all over the entire stent. Given the fact that the crown is a
critical  region in a  stent,  we propose that  an optimal  depot  stent  should have through-
hole reservoirs on the stent bar arms and/or connectors for the maximum drug capacity
without  compromising  its  mechanical  integrity  significantly.  It  should  be  noted  that
although the  depot  stent  has  the  wonderful  feature  of  precise  and programmable  drug
release control, it was found that its fatigue safety factor could be compromised to certain
degrees for all various forms of the depot stent.
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Figure 9. Contour plot of the PEEQ of the standard stent (top) and the depot stent with through-hole reservoirs (bot‐
tom) at expansion with a magnified view of the stent crown in the right window.
Figure 10. Radial strength comparison of the standard stent and the depot stent with through-hole reservoirs.
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5.3. Depot stent drug capacity
A typical DES (3-ring model) with a 5 μm coating thickness carries a total drug-polymer
volume of 0.0535 mm3 (Table 3). For the depot stent, our chosen reservoir size is 50% of the
strut width and 100% completely through the strut thickness. Such a design is able to carry
approximately 0.0004 mm3 of drug-polymer mix per reservoir. Therefore, by creating 135
through-hole reservoirs on the 3-ring depot stent model, its total reservoir capacity is enough
to fully replace the surface coating layers of 0.0535 mm3 on a typical drug-eluting stent. This
helps to completely eliminate the surface coating layers and thus reduce the overall stent
profile.
Figure 11. Goodman diagram comparison of the standard stent (top) and the depot stent with through-hole reservoirs
(bottom).
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The density and size of the reservoirs could be changed to increase the total drug capacity of
the depot stent. For example, the total volume of the drug-polymer mix can be quadrupled to
0.221 mm3 when the through-hole reservoirs are evenly distributed on the entire stent, as
shown in Figure 3(d). Our proposed depot stent in the next section, same stent as the one in
Figure 3(d) without reservoirs on the crowns, also triples the total volume to 0.149 mm3.
Model Number ofreservoirs
Drug-polymer compound
carried (mm3)
5-μm thickness coating on stent surface - 0.0535
Through-hole reservoir (per reservoir) - 0.0004
Through-hole reservoirs on CO 30 0.012
Through-hole reservoirs on BA 270 0.108
Through-hole reservoirs on CR 270 0.108
Through-hole reservoirs on entire stent 552 0.221
Proposed depot stent 372 0.149
Table 3. Estimated drug capacity of a depot stent (3-ring model).
5.4. Proposed depot stent and its variations
5.4.1. Proposed depot stent
We propose an optimal depot stent, with reservoirs uniformly distributed on the entire stent
except the crown region, to increase the total drug capacity without comprising its mechanical
Figure 12. Variation of key clinically relevant functional attributes versus drug reservoir depth.
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integrity significantly (Figure 13). This depot stent has eight reservoirs on the connectors and
six reservoirs on the bar arms, with the spacing of approximately 0.15 mm between two
reservoirs. Simulation results on the variations of major clinical attributes are listed in Tables
4 along with those on other stents for comparison. Figure 14 shows the contour plot comparison
of the equivalent plastic strain developed at the expansion stage among the standard case, the
depot stent with through-hole reservoirs on the entire stent, and the proposed depot stent. For
the proposed depot stent, the maximum equivalent plastic strain was actually reduced by 9%
and the strain distribution was spread out even more uniformly than the standard case. This
was attributed to the creation of through-hole reservoirs on the bar arms, effectively shifting
the stress–strains away from the crown reservoirs and re-distributing them along the crown
arcs. The radial strength only dropped by 10%. The fatigue safety factor was reduced margin‐
ally by 13% when compared to the standard case, whereas the very same stent but with
through-hole reservoirs on the entire stent showed a staggering 34% reduction. This significant
gain in fatigue safety factor was partially due to the removal of through-hole reservoirs on the
crowns and partially due to the stress–strain redistribution mentioned above.
To sum up, the total drug capacity of our proposed depot stent could be tripled, with only
marginal trade-off in major clinical attributes: its radial strength and the fatigue safety factor
were reduced by only 10% and 13%, respectively. Therefore, this depot stent could carry more
drugs and deliver them more smartly than the modern drug-eluting stents, thereby opening
up a wide variety of new treatment opportunities such as the renal disease or cancer target
therapy.
Figure 13. Proposed depot stent with a magnified view of the stent mesh in the right window.
5.4.2. Effects of reservoir shape
Besides the circular (cylindrical if considering depth) reservoirs aforementioned, other
reservoir shapes were also investigated, for example, hexagonal and square reservoirs (Figure
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15). The length on each side of the hexagonal and square reservoirs (0.0349 mm and 0.0563
mm, respectively) was determined in a way that each reservoir capacity was identical to that
of a circular reservoir. The location of the reservoir center remained unchanged.
Table 4 lists the mechanical integrity of the depot stent as a function of the reservoir shape.
Simulation results show that the changes in the reservoir shape caused little differences in
Figure 14. Contour plot of the equivalent plastic strain of the standard stent (top), the depot stent with reservoirs on
the entire stent (middle), and the proposed depot stent (bottom) at expansion with a magnified view of the stent crown
in the right window.
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equivalent plastic strain and radial strength, with approximately 10% across-the-board
reductions when compared to the “standard” stent. In terms of the fatigue safety factor, the
hexagonal reservoir had a slight 5% advantage over the circular and square reservoirs. This
could be attributed to the stress re-distribution within the stent and the hexagonal reservoir
makes a bigger impact than reservoirs with other shapes.
Figure 15. Depot stent with (a) hexagonal and (b) square reservoirs.
Model RS(N/mm)
Variation
(%)
PEEQ
(%Strain)
Variation
(%) FSF
Variation
(%)
Standard 3.78 - 40.5 - 3.05 -
Proposed depot stent 3.41 -9.79 36.7 -9.38 2.66 -12.79
Hexagonal reservoir 3.43 -9.26 36.4 -10.12 2.80 -8.20
Square reservoir 3.38 -10.58 36.1 -10.86 2.65 -13.11
Table 4. Effects of reservoir shape on stent mechanical integrity.
5.4.3. Effects of reservoir size and number
Effects of the reservoir size and number of the depot stent were also investigated (Figure 16).
The total drug loading capacity on each bar arm/connector was intended to maintain the same,
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whereas the size and number of the reservoirs were adjusted accordingly. Stent variation #1
had smaller but more reservoirs, with 8 reservoirs on the bar arms and 10 reservoirs on the
connectors; on the other hand, stent variation #2 had larger but fewer reservoirs, with four
reservoirs on the bar arms and six reservoirs on the connectors. In all cases, the total length
between the farther edges of two end reservoirs remained unchanged.
Table 5 lists the mechanical integrity of the depot stent as a function of the reservoir size and
number. Simulation results show that, for the same drug loading capacity, stent variation #2
with larger and fewer reservoirs yielded lower radial strength, but smaller equivalent plastic
strain and thus higher fatigue safety factor. In addition, the fatigue safety factor seems to be
more sensitive than the equivalent plastic strain and radial strength in this case. Its value
increased from 2.36 to 2.88, a 17% jump from stent variation #1 to #2, which is consistent with
the earlier observation. Therefore, stent variation #2 of larger and fewer reservoirs is a better
candidate for drug delivery; its total drug capacity could be tripled with marginal trade-off in
its major clinical attributes: the radial strength and fatigue safety factor were reduced by only
11% and 6%, respectively.
Model RS(N/mm)
Variation
(%)
PEEQ
(%Strain)
Variation
(%) FSF
Variation
(%)
Standard 3.78 - 40.5 - 3.05 -
Proposed depot stent 3.41 -9.79 36.7 -9.38 2.66 -12.79
Variation #1 3.48 -7.94 37.6 -7.16 2.36 -22.62
Variation #2 3.38 -10.58 34.8 -14.70 2.88 -5.57
Table 5. Effects of reservoir size and number on stent mechanical integrity.
Figure 16. Proposed depot stent and its variation #1 and #2.
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5.5. Depot stent prototyping
In this study, the input laser parameters used for cutting stents are listed as follows: average
power 37.5 W, pulse repetition rate 80 KHz, cutting speed 5 mm/s, and Argon pressure 12 bar.
Optical microscopy was used to measure the kerf width and observe the surface conditions of
each stent.
Figure 17 shows the relationship of the average kerf width vs. the distance between the laser
source and hypotube surface. The kerf width had the minimum value of 23.2 μm at the distance
of 0.37 mm. When the distance was between 0.27 mm and 0.51 mm, the laser beam was able
to penetrate through the hypotube, resulting in successful cutting within a focal-depth range
of 0.24 mm. Figure 6 is the depot stent design pattern cut onto a seamless hypotube by laser
prior to material removal and electro-polishing.
Figure 17. Average kerf width vs. distance between laser source and hypotube surface.
The polishing conditions for surface finishing of depot stent prototypes are listed in Table 6.
Figure 18 shows the depot stent prototype before and after electro-polishing. These stents were
able to achieve high quality of mirror-like surface finishing after polishing. Figure 19 is the
prototype of our proposed depot stent of 2 mm diameter and 22 mm long for demonstration
of our design concept.
Stirring speed
(RPM)
Current
(A)
Time
(sec)
Temperature
( Co  )
500–550 0.242 105–135 50–55
Table 6. Electro-polishing conditions for surface finishing of depot stents.
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Figure 18. Surface conditions of manufactured depot stents before (left) and after (right) electro-polishing.
Figure 19. Prototype of our proposed depot stent.
6. Conclusion
The depot stent with micro-sized drug reservoirs is a novel concept for smart drug delivery
and provides a promising future for highly controlled release of different medications with
programmable spatial/temporal control. However, creating such drug reservoirs on the stent
struts inevitably weaken the stent scaffolding and compromise its mechanical integrity. The
impact of these drug reservoirs on major clinical attributes of the depot stent was systematically
investigated. Several conclusions were drawn from this study:
i. The reservoirs on either bar arms or connectors had little effects in equivalent plastic
strain and radial strength when compared to the “standard” drug-eluting stent.
However, the fatigue safety factor was reduced more significantly, suggesting that
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the depot stent is resistant to acute stent fracture or vessel collapse but susceptible to
long-term stent fatigue failure.
ii. Creating reservoirs on the crown region of the depot stent has the most significant
impact among all major locations.
iii. The degradation in mechanical integrity is more sensitive to reservoir location than
reservoir depth.
iv. The hexagonal reservoirs resulted in a marginal increase in fatigue resistance when
compared to the circular and square reservoirs.
v. For the same drug loading capacity, larger and fewer reservoirs resulted in a
noticeable increase in the fatigue resistance over smaller and more reservoirs.
vi. Our proposed depot stent was proven to be a feasible design. Its total drug capacity
could be tripled with acceptable/marginal trade-off in major clinical attributes: the
radial strength and the fatigue safety factor of our proposed depot stent were reduced
by only 10% and 13%, respectively.
vii. A prototype of our proposed depot stent (2 mm diameter and 22 mm long) was
manufactured for the feasibility demonstration of our design concept.
This study can serve as a guideline to help future depot stent designs to achieve the best
combination of stent mechanical integrity and smart drug delivery.
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